Personalized strength, balance and treadmill perturbation program to reduce falls in people with multiple myeloma
Official title: Investigation of Fall Risk Factors and Implementation of an Exercise Intervention for Prevention of Falls in Patients With Multiple Myeloma
Run by University Hospital Heidelberg · NCT07044427 · Data updated 2026-11-12
This program tests whether a tailored combination of strength, balance, and treadmill perturbation exercises can reduce fall risk in adults receiving treatment for multiple myeloma.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | University Hospital Heidelberg Academic / other |
| Locations | 1 site (Heidelberg, Baden Würtemberg) |
| Status | Recruiting |
| Started | February 2, 2024 |
| Main results expected | December 30, 2026 |
| Study ends | December 30, 2026 |
| Registry record updated | January 22, 2026 |
| Trial ID | NCT07044427 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with multiple myeloma receiving systemic therapy for at least six months, ECOG status ≤3, able and willing to perform the training program at least three times per week, attend follow-up visits, provide informed consent, and read/speak sufficient German.
✕Probably not a fit
Patients with physical or cognitive limitations that prevent safe participation in the exercise sessions or those unwilling/unable to attend regular training and follow-ups are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants will receive a baseline fall-risk assessment to identify contributors such as muscle weakness, balance deficits, or other risk factors. Enrolled patients will follow a patient-specific exercise program combining supervised strength and balance training with treadmill-based perturbation sessions, performed at least three times weekly. The protocol includes regular follow-up visits to track changes in fall-risk measures, functional performance, and incidence of falls. The study aims to map fall risk factors in multiple myeloma patients and see if a structured exercise intervention lowers falls and related injuries.
Why it matters
Potential benefit: If successful, the program could reduce falls and fall-related injuries, helping patients maintain mobility and independence.
How similar studies have gone: Strength and balance training—and emerging perturbation training—have reduced falls in older adults, but these approaches have been little tested specifically in multiple myeloma patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with multiple myeloma requiring therapy (at least 6 months of systemic therapy) * ECOG status ≤ 3 * Age ≥18 years * Patients who state that they want to carry out the training program at least 3 times/week and participate in the planned follow-up visits * Ability to give informed consent * Written consent to participate in the study * Sufficient written and spoken German to complete the questionnaire Exclusion Criteria: * Any physical or mental limitations that would prevent participation in the training program or the planned follow-up checks.
Where it's running
-
University Hospital Heidelberg
Heidelberg, Baden Würtemberg, Germany Recruiting
Study contacts
- Study coordinator: Ulrike Dapunt, prof. Dr. med
- Email: ulrike.dapunt@med.uni-heidelberg.de
- Phone: +49 622156 32765
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma
In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.
-
Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma
This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.
-
SMS text check-ins to track symptoms for people with plasma cell disorders
This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.
-
Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma
This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.